Can a new eyedrop heal the cornea in dry eye disease?
NCT ID NCT06370039
First seen Sep 18, 2026 · Last updated Sep 18, 2026
Summary
Researchers are testing an experimental eyedrop called INV-102 in adults with moderate to severe dry eye disease. The trial compares INV-102 with a vehicle drop over four weeks of repeated dosing. The main goal is to see whether INV-102 reduces corneal damage, measured by a standard staining score. About 109 participants will take part.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- INV-102 ophthalmic solution, an experimental eyedrop
- What this could lead to
- If INV-102 works, it could offer a new eyedrop that helps repair the cornea in people with moderate to severe dry eye disease.
- What could go wrong
- This is a Phase 2 trial with about 109 participants, so it may not show a clear benefit or the results may not hold in larger studies. Eyedrops can cause stinging, irritation, or other eye side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
109 people
The number who actually took part.
- Started
-
Mar 2024
- Finished
-
Jul 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 74 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Subjects ≥18 and \<75 years of age * Presence of moderate to severe dry eye disease (DED) in at least one eye Key Exclusion Criteria: * Presently using prescription eyedrops, except those used for dry eye disease, which must be discontinued 4 weeks prior * Use of over-the-counter (OTC) eyedrops except for lubricant eyedrops or artificial tears, within 1 week prior to initiation of study drug dosing * History or evidence of ocular infection within the previous 30 days * Blepharitis or meibomian gland disease requiring the use of either topical or systemic antibiotics within 2 months * Allergic conjunctivitis requiring treatment within 30 days * Unable to discontinue contact lens wear for 2 weeks prior and for the duration of the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dry eye disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
iuvo BioScience
Rush, New York, 14543, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two eye gels go head to head for dry eye relief
- Can a daily eye drop safely treat dry eye? phase 3 trial puts tivanisiran to the test
- Can tiny fat bubbles in eye drops soothe dry eyes?
- Can a new eye drop fully clear dry eye redness?
- Could a common dry eye drop shield the Cornea's inner layer?
- Dry eye gel may sharpen cataract surgery results